Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neurotoxin-based models of Parkinson's disease
Jordi Bové, Céline Perier
Neuroscience (2011) Vol. 211, pp. 51-76
Closed Access | Times Cited: 483

Showing 1-25 of 483 citing articles:

Rodent models in neuroscience research: is it a rat race?
Bart Ellenbroek, Jiun Youn
Disease Models & Mechanisms (2016) Vol. 9, Iss. 10, pp. 1079-1087
Open Access | Times Cited: 533
Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity
David Val‐Laillet, Esther Aarts, Bernd Weber, et al.
NeuroImage Clinical (2015) Vol. 8, pp. 1-31
Open Access | Times Cited: 411
LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals
Miryam Nava Catorce, Goar Gevorkian
Current Neuropharmacology (2016) Vol. 14, Iss. 2, pp. 155-164
Open Access | Times Cited: 319
The Role of Innate and Adaptive Immunity in Parkinson's Disease
George T. Kannarkat, Jeremy M. Boss, Malú G. Tansey
Journal of Parkinson s Disease (2013) Vol. 3, Iss. 4, pp. 493-514
Open Access | Times Cited: 298
Alpha-synuclein and tau: teammates in neurodegeneration?
Simon Moussaud, Daryl Jones, Elisabeth L. Moussaud-Lamodière, et al.
Molecular Neurodegeneration (2014) Vol. 9, Iss. 1
Open Access | Times Cited: 248
PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson’s Disease Pathobiology?
Dominika Truban, Xu Hou, Thomas R. Caulfield, et al.
Journal of Parkinson s Disease (2016) Vol. 7, Iss. 1, pp. 13-29
Open Access | Times Cited: 214
Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity
Sunil Srivastav, Sabita Neupane, Sunil Bhurtel, et al.
The Journal of Nutritional Biochemistry (2019) Vol. 69, pp. 73-86
Closed Access | Times Cited: 162
Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss
Yunjong Lee, Senthilkumar S. Karuppagounder, Joo‐Ho Shin, et al.
Nature Neuroscience (2013) Vol. 16, Iss. 10, pp. 1392-1400
Open Access | Times Cited: 198
Inflammation in Parkinson's Disease
Kemal Uğur Tüfekçi, Ralph Meuwissen, Şermin Genç, et al.
Advances in protein chemistry and structural biology (2012), pp. 69-132
Closed Access | Times Cited: 191
Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease
Zaijun Zhang, Guohui Li, Samuel S.W. Szeto, et al.
Free Radical Biology and Medicine (2015) Vol. 84, pp. 331-343
Closed Access | Times Cited: 146
Epigallocatechin gallate and mitochondria—A story of life and death
Marcos Roberto de Oliveira, Seyed Fazel Nabavi, Maria Daglia, et al.
Pharmacological Research (2015) Vol. 104, pp. 70-85
Closed Access | Times Cited: 146
The potential role of neuroinflammation and transcription factors in Parkinson disease
Prafulla Tiwari, Rishi Pal
Dialogues in Clinical Neuroscience (2017) Vol. 19, Iss. 1, pp. 71-80
Open Access | Times Cited: 146
Zebrafish as an Animal Model for Drug Discovery in Parkinson’s Disease and Other Movement Disorders: A Systematic Review
Rita L. Vaz, Tiago F. Outeiro, Joaquim J. Ferreira
Frontiers in Neurology (2018) Vol. 9
Open Access | Times Cited: 139
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Christian Hölscher
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 4, pp. 333-348
Open Access | Times Cited: 135
A partial lesion model of Parkinson's disease in mice – Characterization of a 6-OHDA-induced medial forebrain bundle lesion
Jordi Boix, Thomas Padel, Gesine Paul
Behavioural Brain Research (2015) Vol. 284, pp. 196-206
Open Access | Times Cited: 132
Distinct Effects of Rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on Cellular Bioenergetics and Cell Death
Samantha Giordano, Jisun Lee, Victor Darley‐Usmar, et al.
PLoS ONE (2012) Vol. 7, Iss. 9, pp. e44610-e44610
Open Access | Times Cited: 125
NADPH oxidases in Parkinson’s disease: a systematic review
Karim Bélarbi, Elodie Cuvelier, A. Destée, et al.
Molecular Neurodegeneration (2017) Vol. 12, Iss. 1
Open Access | Times Cited: 123
Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice
Monica R. Langley, Anamitra Ghosh, Adhithiya Charli, et al.
Antioxidants and Redox Signaling (2017) Vol. 27, Iss. 14, pp. 1048-1066
Open Access | Times Cited: 121
Targeting urate to reduce oxidative stress in Parkinson disease
Grace F. Crotty, Alberto Ascherio, Michael A. Schwarzschild
Experimental Neurology (2017) Vol. 298, pp. 210-224
Open Access | Times Cited: 115
Pharmacological Targeting of Microglial Activation: New Therapeutic Approach
Caiyun Liu, Xu Wang, Chang Liu, et al.
Frontiers in Cellular Neuroscience (2019) Vol. 13
Open Access | Times Cited: 114
Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model
Ping Zhang, Lingyu Zhang, Lin Li, et al.
Neuropeptides (2018) Vol. 71, pp. 70-80
Closed Access | Times Cited: 112
Exercise: Is it a neuroprotective and if so, how does it work?
Michael J. Zigmond, Richard J. Smeyne
Parkinsonism & Related Disorders (2013) Vol. 20, pp. S123-S127
Closed Access | Times Cited: 110
Animal Models of Parkinson’s Disease
Elena A. Konnova, Maria Swanberg
Codon Publications eBooks (2018), pp. 83-106
Open Access | Times Cited: 104
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson’s disease
George E. Barreto, Alexandre Iarkov, Valentina Echeverrı́a
Frontiers in Aging Neuroscience (2015) Vol. 6
Open Access | Times Cited: 103
Neuroprotective effects of fingolimod in mouse models of Parkinson's disease
Peng Zhao, Xiaoxia Yang, Liu Yang, et al.
The FASEB Journal (2016) Vol. 31, Iss. 1, pp. 172-179
Closed Access | Times Cited: 103
Page 1 - Next Page

Scroll to top